Going Viral Episode 207

In this episode:

• Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time
• COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed
• How the Pfizer vaccination’s lack of impact on transmission is not cause for concern and was clearly communicated since its release. The main impact is the reduction of severity, hospitalisations and death, and the data for this hasn’t changed
• How a nasal vaccination might be coming

Host: Dr David Lim, GP and Medical Educator

Total time: 21 mins

Guest: A/Prof Paul Griffin, Infectious Diseases Physician and Clinical Microbiologist
 

This Healthed educational segment is supported by Moderna Australia. The views expressed by the experts are entirely their own.